Show simple item record

dc.contributor.authorMariam, NBG
dc.contributor.authorSong, YP
dc.contributor.authorJoseph, N
dc.contributor.authorHoskin, P
dc.contributor.authorReeves, K
dc.contributor.authorPorta, N
dc.contributor.authorJames, N
dc.contributor.authorChoudhury, A
dc.date.accessioned2021-11-02T10:33:58Z
dc.date.available2021-11-02T10:33:58Z
dc.date.issued2021-08-17
dc.identifier.citationOncotarget, 2021, 12 (17), pp. 1729 - 1733
dc.identifier.issn1949-2553
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4867
dc.identifier.eissn1949-2553
dc.identifier.doi10.18632/oncotarget.28023
dc.description.abstractOne third of patients with bladder cancer present with muscle invasive bladder cancer (MIBC) which has a poor prognosis. International guidelines for the management of MIBC recommend radical cystectomy or bladder-preserving treatment based on radical radiotherapy with a form of radiosensitisation. In the UK, both conventional fractionation with 64 Gy in 32 fractions and hypofractionation with 55 Gy in 20 fractions are standard of care options with the choice varying between centres. A meta-analysis of individual patients with locally advanced bladder cancer from two UK multicentre phase 3 trials was published recently. This study evaluated the non-inferiority of a hypofractionated schedule compared to a conventional regime. This analysis confirmed the non-inferiority of the hypofractionated regimen, and noted superior locoregional control. We discuss the relevance of these findings to current practice while considering the radiobiology of hypofractionation, the role of systemic therapies and radiosensitisation, as well as the socioeconomic benefits.
dc.formatElectronic-eCollection
dc.format.extent1729 - 1733
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleHypofractionation: less is more?
dc.typeJournal Article
dcterms.dateAccepted2021-06-21
rioxxterms.versionVoR
rioxxterms.versionofrecord10.18632/oncotarget.28023
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2021-08-17
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfOncotarget
pubs.issue17
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit
pubs.publication-statusPublished
pubs.volume12
pubs.embargo.termsNot known
icr.researchteamClinical Trials & Statistics Unit
dc.contributor.icrauthorPorta, Nuriaen_US


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0